Objective: The aim of the study was to evaluate the prevalence and association of subjective symptoms and objective signs of vaginal atrophy (VA).
I n postmenopausal women vaginal atrophy (VA), as a consequence of acquired hypoestrogenism, is part of the syndrome now termed genitourinary syndrome of menopause. 1 Anatomical modifications of the vagina are characterized by mucosal dryness, pallor, thinning, fragility, and the presence of petechiae. These are inevitably associated with an increase of vaginal pH, an indirect index of a poor maturation of vaginal epithelium. 2, 3 Symptoms of VA referred by women include vaginal dryness, dyspareunia, itching, burning, and often dysuria. 2, 3 The prevalence and time course of both objective modifications and subjective symptoms are not really determined. Most epidemiological studies performed on VA are represented by surveys aimed to evaluate bothersome symptoms in women affected by VA. [4] [5] [6] [7] [8] [9] [10] Such studies did not include an objective evaluation of the vagina, and were directed mostly to symptomatic women. It is reported that the prevalence of symptoms ranges between 10% and 40% of postmenopausal women with studies reporting up to 60%. [11] [12] [13] Those studies do not clarify whether the prevalence increases with age and whether it is related to a specific anatomic modification of the vagina. Indeed also for objective signs of VA there is no clear data on prevalence and time course of occurrence. Only one study evaluated the prevalence of pH > 5 in a population of women stratified by age categories. 14 The aim of this investigation is to evaluate the prevalence, prevalence stratified by years since menopause, and concordance between objective signs and subjective symptoms of VA in a large sample of postmenopausal women.
METHODS
A multicenter cross-sectional study was conducted between December 2013 and March 2014 in 22 Italian outpatient gynecological centers (13 in the north, 4 in the center, and 5 in the south of Italy). 15 Women in postmenopause asking for medical consultation of any type were consecutively recruited. Each center had to enroll at least 30 postmenopausal women for the study. Finally, all of the centers met the inclusion criteria for recruiting between 35 and 50 participants each. To reach a uniform evaluation of objective vaginal signs, a pre-meeting course was set for all those physicians effectively involved in the study. For each center it was requested that a single trained physician performed all the evaluation.
Study population
Eligible participants were white women in postmenopause-in the presence of amenorrhea for at least 12 months-connected with the gynecological services for routine gynecological examination, who signed an informed consent to participate in the research study. The ethics committee of the centers involved approved the study, and no financial incentive was offered to any of the participants.
Data collection
After signing an informed consent, each woman underwent a medical interview where basic demographic information, personal and family history, and comorbidities were collected. Thereafter, the presence of signs and symptoms of VA was investigated by a trained physician. Objective signs taken into considerations were a vaginal pH > 5, thinning of vaginal rugae, mucosal dryness, pallor of the mucosa, mucosal fragility, and the presence of petechiae. Each objective symptom was scored in a 0 to 3 scale with 0 ¼ absent, 1 ¼ slight, 2 ¼ moderate, and 3 ¼ severe. The presence of a vaginal infection and previous or actual use of therapies for VA was investigated, as well. Before the examination each participant self-reported in a 0 to 3 scale the intensity of symptoms of VA experienced in the last month such as vaginal dryness, dyspareunia, itching, burning, and dysuria.
Statistical analysis
All signs and symptoms were collected in an anonymous medical record and then transferred to a computer database. The prevalence of each sign or symptom of VA, independently of its intensity, was stratified into categories of years since menopause. The kappa (k) measure of agreement was calculated to evaluate the concordance between subjective symptoms and objective signs. K values ranged from 0 (no agreement) to 1 (maximum agreement). 16 The capability of each objective sign to detect a subjective symptom was assessed by evaluating the sensitivity and specificity between the two. Logistic regression analysis was used to define the prediction of each symptom by independent variables. Single regression analyses were performed to evaluate the relation between subjective symptoms and each single objective sign of VA or women characteristics. Logistic models for subjective vaginal dryness, dyspareunia, burning, itching, or dysuria were constructed to include those variables significantly associated with such symptoms (model 1) or all the variables evaluated (model 2). Covariates included in the models were categorical variables such as objective vaginal pH > 5 (yes/no), vaginal dryness (yes/no), vaginal thinning (yes/no), fragility (yes/no), the presence of petechiae (yes/no), type of menopause (medical, surgical, physiological), sedentary lifestyle (yes/no of <30 min/wk of leisure activity), use of alcohol (yes/no), smoking (yes/no), actual (yes/no) or previous (yes/no) use of systemic hormone therapy or any type of local (hormonal or nonhormonal) therapy for VA, recent (within 3 mo) or actual presence (yes/no) of vaginal infections, and continuous variables such as years since menopause, age, and body mass index (m/kg 2 ).
Analyses were performed by the statistical package Stat-View 5.01 (SAS Institute Inc, Cary, NC). All results are expressed as the means and SDs. A P < 0.05 was considered as statistically significant.
Sample size calculation
On the basis of previous studies, 9, 11 we considered the prevalence of VA of 40.0% (95% CI AE 3.5%). It was estimated that the research study required 753 women to obtain a reliable estimate of VA.
RESULTS
Among 927 eligible women, 913 gave their informed consent to participate in the study. Women had a mean age of 59.3 AE 7.4 years and were in menopause since 10.3 AE 8.8 years. Among these women, 83.3% were in physiological menopause, 10.1% were in surgically induced menopause (oophorectomy), 6.6% in nonphysiological menopause defined as premature ovarian failure (last menstruation <40 y), early menopause (last menstruation between 40 and 45 y), or menopause induced by radiological or pharmacological cause.
Objective signs of VA
Objective signs of VA showed a different prevalence. A pH > 5 was evident in 87.4% of women, vaginal dryness in 78.1%, mucosal pallor in 77.8%, vaginal rugae thinning in 75.6%, mucosal fragility in 52.4%, and petechiae in 32.4% ( Table 1) .
The prevalence of signs in women stratified by years since menopause was also different ( Fig. 1) . A basic pH was evident in 78% of women 1 year after menopause, rising to the value of 90% in women evaluated 10 years after menopause. Mucosal pallor, rugae thinning, and objective vaginal dryness showed the same trend of prevalence with values of 60% to 62% 1 year after menopause to values of 90% in women evaluated 20 years after menopause. The prevalence of mucosal fragility was around 35% in women in the first 6 years after menopause to reach values of 80% in women evaluated 20 years after menopause. The prevalence of petechiae was 15% to 20% in women in the first years after menopause to reach values of 51% in women evaluated 20 years after menopause. At the moment of investigation almost 6.2% of the women were suffering from vaginal infection, and almost 7.5% of them had suffered from vaginal infection in the previous 3 months. The prevalence of infections fluctuated in the different categories of women stratified by years since menopause, without a clear pattern.
Subjective symptoms of VA
The prevalence of symptoms was different. Vaginal dryness was present in 77.1%, dyspareunia in 62.4%, itching in 44.1%, burning in 41.6%, and dysuria in 20.2% of women ( Table 1 ). The prevalence of symptoms in women stratified by years since menopause was also different ( Fig. 1 ). Vaginal dryness was present in 62% to 67% of women 1 year after menopause to reach values above 85% in women evaluated 10 years after menopause and thereafter. The prevalence of dyspareunia was 67.5% in women in the first year after menopause, reaching a maximal level of 75% in women 6 years after menopause and then was lower in women with more years since menopause with a prevalence of 41% in women evaluated 20 years after menopause. The prevalence of itching and burning was 40% and 48% in women 1 year after menopause and did not differ too much in the other group of women, reaching maximal values of 50% and 52%, respectively. Dysuria was around 15% in women evaluated in the first years after menopause and its prevalence was almost double in women evaluated 20 years after menopause.
Therapies for VA
The prevalence of women actually receiving therapy for VA was low ( Table 1) .
At the moment of investigation 28.1% women were on treatment for VA, of which 10.9% were receiving systemic SYMPTOMS AND SIGNS OF VAGINAL ATROPHY (4.1% nonhormonal and 6.8% hormonal) and 17.2% vaginal (11.4% nonhormonal and 5.8% hormonal) therapy ( Table 1 ). The prevalence of treatment was 10.8% in women evaluated in the first year after menopause, and was maximal (39.4%) in women evaluated in the second year after menopause. The prevalence was about 28% to 30% in women of the other group and was higher again (37.3%) in women 20 years after menopause ( Fig. 1 ).
Association of signs and symptoms
The k measure of agreement between subjective and objective symptoms is shown in Table 2 . A high k value was observed only for the concordance between subjective and objective vaginal dryness (k ¼ 0.820), and lower values for subjective vaginal dryness and objective vaginal mucosal pallor (k ¼ 0.512) and thinning (k ¼ 0.573). In all other cases k value was below 0.5. To better understand the k value, the sensitivity and specificity linking each objective sign to each subjective symptom is added. Predicting factors (objective signs and general characteristics of women) of each subjective symptom were determined by mean of logistic analysis models (Table 3) . Vaginal dryness was associated with the objective sign of vaginal dryness, vaginal pallor, and a sedentary life (Table 3 ). Dyspareunia was associated mainly with vaginal dryness and rugae thinning, and inversely to age. Vaginal burning was associated with vaginal dryness, pallor, fragility, and the presence of petechiae. Vaginal itching was associated with rugae thinning, pallor, and the presence of petechiae. Finally, dysuria was associated with vaginal fragility and the presence of petechiae. Previous or actual use of a therapy for VA did not protect from symptoms. 
DISCUSSION
In this study, subjective symptoms of VA were related to objective indexes of vaginal hypoestrogenism such as vaginal pH, and to the physician objective evaluation of VA signs. By assessing both objective signs and subjective symptoms of VA, we had the possibility to evaluate their prevalence, their prevalence categorized by years since menopause, and their association.
The data show that VA is a composite picture in which both signs and symptoms show a different prevalence. Estrogen stimulation produces copious amounts of glycogen. Döderlein's lactobacilli depend on glycogen from sloughed vaginal cells. 17 Lactic acid produced by these bacteria lowers vaginal pH levels to 3.5 from 4.5. Low levels of estrogens do not allow maturation of vaginal epithelium and lead to an increase of pH. A pH value above 5 is an objective index consistent with VA and appropriate to define the menopause status. 14, 18 In a previous study, population-based, prevalence of a pH > 5 was found to increase from 60% of women 50 to 54 years of age to values of 90% in older ages. 14 Our data confirm that 10 to 20 years after menopause prevalence of a pH > 5 is present in about 90% of women, and also show that a pH > 5 is already present in 78% of women 1 year after menopause. The difference of prevalence in younger postmenopausal women observed in the two studies can be due to the different categories of women (age vs years since menopause), the different race/nationality of the two populations, and the study design (population vs women of outpatient services). A low pH is essential for the body's natural defense against vaginal and urinary tract infections. 19 A pH > 5 changes vaginal microbiota, 20 and predisposes the vagina to infection by streptococci, staphylococci, coliforms, and diphtheroid. 17 In our study, the rate of vaginal infection in the 3 months preceding the investigation was around 7.5%. The presence of infections did not affect any of the symptoms evaluated for VA. Risk factors for vaginal infections seemed to be represented by all those indexes indicating a pronounced VA, such as vaginal petechiae, need for treatments and smoking, whose role as risk factor for VA has already been reported. 21 When stratified by years since menopause objective indexes of reduced tropism of vaginal mucosa, such as vaginal dryness, mucosal pallor and rugae thinning, show a similar prevalence. In the years immediately after menopause their prevalence is lower than that of pH > 5, being present in 60% of women 1 year after menopause. Then, it progressively increases to reach, 20 years after menopause, the same prevalence found for pH > 5. Much less prevalent is the presence of vaginal fragility and/or petechiae. These manifestations can be considered the most extreme and late signs of VA, with a prevalence that is low immediately after menopause, but markedly increases after 20 years. The prevalence of subjective VA symptoms does not completely match the one described for the objective signs. The prevalence of some symptoms, such as vaginal dryness, parallels the objective evidence of vaginal dryness, mucosal pallor, and rugae thinning. Its prevalence is already high 1 year after menopause and then progressively increases, similarly to objective signs. Factors independently associated with vaginal dryness are the objective evidence of vaginal dryness and a sedentary life. The effect of the latter is not clear, but it has been reported that sedentary women have an almost 2.6 times risk to have sexual dysfunction. 22 Continued sexual function may prevent or delay the risk of developing VA. [22] [23] [24] VA is believed to represent a risk factor for sexual dysfunction, 12 although the direct relation between sexual problems and objective signs of VA is not straightforward. 25 Pain at intercourse was reported to be less, 9, 26 or similarly 12,27 prevalent than vaginal dryness. In our investigation we simply collected the presence of the referred symptom pain at intercourse. The results show that in the first years after menopause the prevalence of dyspareunia is similar to that of vaginal dryness, the latter representing the main independent factor associated with the former. The other independent factor inversely associated with the prevalence of dyspareunia is age. Indeed, rate of dyspareunia increases up to 6 years after menopause, in parallel to vaginal dryness, and then progressively declines. This late dichotomy between vaginal dryness and dyspareunia can be explained by a progressive withdrawal from intercourse occurring with time, either for sexual discomfort or aging. [28] [29] [30] Unfortunately, this 
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information was not collected in our study. Other symptoms of VA such as vaginal burning, vaginal itching, or even dysuria did not progress with time. The prevalence of these symptoms ranged around the values observed 1 year after menopause, values that were similar to those found 20 years after menopause. Recognized therapies for VA are represented by systemic or vaginal treatments. 3 In our case, use of vaginal therapies was more prevalent and in particular of nonhormonal therapies (gel, moistures). In contrast to the high prevalence of signs and symptoms of VA, the prevalence of treatments was only 28%. A peak of therapy was observed in the second year after menopause. This peak coincided with a downward peak of all VA symptoms. Likely treatments were sufficient to furnish a temporary relief from symptoms, without significantly modifying the prevalence of objective signs of VA. Similarly, in the 20 and more years after menopause covered by the investigation, therapy was given to women with most extreme VA, and being on therapy or having gone through therapy represented a risk factor for the presence of dyspareunia, vaginal burning, and dysuria. The present study has several limitations. The study is a multicenter study. Physicians of the different recruiting centers were trained to furnish a uniform evaluation of objective vaginal signs, but evaluation differences may have occurred. Such variability should have been reduced, taking into account, as we have done, only the presence or the absence of a sign rather than its degree of intensity. Some aspects were roughly investigated. We assessed only vaginal pH, without performing any other evaluation of epithelial maturation such as the maturation index that may have furnished additional detailed information. We did not perform any evaluation of woman sexual activity and for this reason we cannot draw any conclusion about the impact of VA on sexual activity and function. Although we collected information about previous and actual use of therapies for VA we did not perform any further investigation on the acceptability, efficacy, and satisfaction related to those therapies. Similar considerations are true for dysuria, where no distinction was performed between the different aspects of the symptom. The study was not conducted in the general population, but on a subset of women requiring a gynecological examination in outpatient centers throughout one single nation. Accordingly, the data cannot be generalized to the entire population. Studies to evaluate the prevalence of VA in general population are difficult to achieve. Online surveys are performed on a particular type of woman, often selected or autoselected on the basis of her symptom, 4-9 without any objective evaluation of the vagina. A population study, the WHI observational study, was performed on a large number of women, but in that case participant selection did occur and objective signs of VA were not collected. 10 CONCLUSIONS The data herein presented indicate that in postmenopausal women of outpatient gynecological services, the prevalence of both objective signs and subjective symptoms of VA is very high and occurs very early after menopause. Signs and symptoms show a different prevalence in the years after menopause and are not strictly associated.
